Pathway for Development and Validation of Multi-domain Endpoints for Amyloid Light Chain (AL) Amyloidosis
Therapeutic Innovation & Regulatory Science · 2024
DOI: 10.1007/s43441-024-00641-6 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Innovation & Regulatory Science, 2024. Verfasst von James Signorovitch und 8 weiteren Autor:innen. Beteiligte Einrichtung: Analysis Group, Boston, USA. Hauptthemen laut MEDLINE: Immunoglobulin Light-chain Amyloidosis, Clinical Trials as Topic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, National Institute on Aging, AbbVie.
Abstract (Originalsprache)
Immunoglobin light chain (AL) amyloidosis is a rare disease in which a plasma cell dyscrasia leads to deposition of insoluble amyloid fibrils in multiple organs. To facilitate development of new therapies for this heterogenous disease, a public–private partnership was formed between the nonprofit Amyloidosis Research Consortium and the US Food and Drug Administration Center for Drug Evaluation and Research. In 2020, the Amyloidosis Forum launched an initiative to identify clinical trial endpoints and analytic strategies across affected organ systems and life impacts via specialized working groups. This review summarizes the proceedings of the Statistical Group and proposes a pathway for development and validation of multi-domain endpoints (MDEs) for potential use in AL amyloidosis clinical trials. Specifically, drawing on candidate domain-specific endpoints recommended by each organ-specific working group, different approaches to constructing MDEs were considered. Future studies were identified to assess the validity, meaningfulness and performance of MDEs through use of natural history and clinical trial data. Ultimately, for drug development, the context of use in a regulatory evaluation, the specific patient population, and the investigational therapeutic mechanism should drive selection of appropriate endpoints. MDEs for AL amyloidosis, once developed and validated, will provide important options for advancing patient-focused drug development in this multi-system disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Analysis Group, Boston, USA.
- US Food and Drug Administration, Silver Spring, USA.
- UK Medicines & Healthcare Products Regulatory Agency, London, UK.
- Janssen Research & Development, Raritan, USA.
- Amyloidosis Research Consortium, 320 Nevada Street, Suite 210, Newton, MA, 02460, USA.
- Amyloidosis Research Consortium, 320 Nevada Street, Suite 210, Newton, MA, 02460, USA. ILousada@arci.org.
Förderung
- NIA NIH HHS
- National Institute on Aging
- AbbVie
- Alexion Pharmaceuticals
- Caelum
- GlaxoSmithKline
- Amyloidosis Research Consortium
Zitieren
APA
Signorovitch, J., Zhang, J., Brown, D., Dunnmon, P., Xiu, L., Done, N., Hsu, K., Barbachano, Y., & Lousada, I. (2024). Pathway for Development and Validation of Multi-domain Endpoints for Amyloid Light Chain (AL) Amyloidosis. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-024-00641-6
Vancouver
Signorovitch J, Zhang J, Brown D, Dunnmon P, Xiu L, Done N, et al. Pathway for Development and Validation of Multi-domain Endpoints for Amyloid Light Chain (AL) Amyloidosis. Therapeutic Innovation & Regulatory Science. 2024. doi:10.1007/s43441-024-00641-6
BibTeX
@article{Signorovitch2024,
author = {Signorovitch, James and Zhang, Jialu and Brown, David and Dunnmon, Preston and Xiu, Liang and Done, Nicolae and Hsu, Kristen and Barbachano, Yolanda and Lousada, Isabelle},
title = {Pathway for Development and Validation of Multi-domain Endpoints for Amyloid Light Chain (AL) Amyloidosis},
journal = {Therapeutic Innovation & Regulatory Science},
year = {2024},
doi = {10.1007/s43441-024-00641-6}
}
EUVIMED